← FDA DRUG APPROVALS

FDA BLA · BLA761297

UNLOXCYT

cosibelimab

Sponsor: CHECKPOINT THERAPEUTICS INC

APPLICATION
BLA761297
TYPE
BLA
ORIGINAL APPROVAL
2024-12-13
LATEST ACTION
2025-11-21
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

UNLOXCYTPrescription
COSIBELIMAB-IPDL 300MG/5ML(60MG/ML) · INJECTABLE · INJECTION

Approval history

2025-11-21Efficacy · Supplement 1 · standardLetterAP
2024-12-13Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →